David T. Hagerty
Keine laufenden Positionen mehr
Karriereverlauf von David T. Hagerty
Ehemalige bekannte Positionen von David T. Hagerty
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| HISTOGEN INC. | Corporate Officer/Principal | 01.10.2014 | 30.09.2019 |
Ardea Biosciences, Inc.
 Ardea Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Ardea Biosciences, Inc. is a biotechnology company which is focused on the development of small-molecule therapeutics for the treatment of serious diseases. The company was founded in January 1994 and is headquartered in Wilmington, DE. | Technik-/Wissenschafts-/F&E-Leiter | 01.01.2011 | 01.01.2013 |
Biogen Idec, Inc. (North Carolina)
 Biogen Idec, Inc. (North Carolina) Pharmaceuticals: MajorHealth Technology Part of Biogen, Inc., Biogen Idec, Inc. (North Carolina) is a pharmaceutical company based in Durham, NC. The company develops pharmaceutical products. Michel Pericles Vounatsos has been the CEO of the company since 2016. | Corporate Officer/Principal | 01.01.2006 | 01.01.2011 |
| Bristol-Myers Squibb Pharmaceutical Research Institute | Corporate Officer/Principal | 01.01.1997 | 01.01.2006 |
Ausbildung von David T. Hagerty
| University of Notre Dame | Undergraduate Degree |
| Saint Louis University School of Medicine | Doctorate Degree |
Statistik
International
| Vereinigte Staaten | 7 |
Operativ
| Corporate Officer/Principal | 3 |
| Undergraduate Degree | 1 |
| Doctorate Degree | 1 |
Sektoral
| Health Technology | 4 |
| Consumer Services | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Private Unternehmen | 4 |
|---|---|
Conatus Pharmaceuticals, Inc.
 Conatus Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Conatus Pharmaceuticals, Inc. is a biotechnology company that focuses on the development and commercialization of novel medicines to treat chronic diseases. The firm engages in developing emricasan, an orally active pan-caspase inhibitor, for the treatment of patients with chronic liver disease and is designed to reduce the activities of human caspases. It also develops CTS-2090, an orally active selective caspase inhibitor, for diseases involving inflammasome pathways. The company was founded by Alfred P. Spada, Jennifer Giottonini Cayer, and Steven J. Mento on July 13, 2005 and is headquartered in San Diego, CA. | Health Technology |
Ardea Biosciences, Inc.
Ardea Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Ardea Biosciences, Inc. is a biotechnology company which is focused on the development of small-molecule therapeutics for the treatment of serious diseases. The company was founded in January 1994 and is headquartered in Wilmington, DE. | Health Technology |
Biogen Idec, Inc. (North Carolina)
Biogen Idec, Inc. (North Carolina) Pharmaceuticals: MajorHealth Technology Part of Biogen, Inc., Biogen Idec, Inc. (North Carolina) is a pharmaceutical company based in Durham, NC. The company develops pharmaceutical products. Michel Pericles Vounatsos has been the CEO of the company since 2016. | Health Technology |
| Bristol-Myers Squibb Pharmaceutical Research Institute |
- Börse
- Insiders
- David T. Hagerty
- Erfahrung
